Table 1.

Table outlining common “favorable” clinical subtypes and recommended treatment compiled from the European Society of Medical Oncology (ESMO) and Spanish Society for Medical Oncology (SEOM) (6, 8).

Clinical subtype	Recommended treatment
Females with isolated axillary adenopathy	As per stages II–III breast cancer
Females with peritoneal adenocarcinomatosis	As per stage III ovarian cancer
Poorly-differentiated neuroendocrine carcinoma	Platinum + Etoposide
Well-differentiated neuroendocrine carcinoma	Somatostatin analogues, 5-fluorouracil
Squamous cell carcinoma with cervical adenopathy	Neck dissection with possible chemotherapy and radiation therapy
Squamous cell carcinoma with inguinal adenopathy	Inguinal node dissection with possible chemotherapy and radiation therapy
Tumor with CK7-/CK20+/CDX2+ molecular profile	As per stage IV colorectal cancer
Single metastatic site	Local resection with possible chemotherapy and radiation therapy
Males with bone metastases and PSA expression	Androgen deprivation therapy with possible radiation therapy